levomilnacipran
Adjunctive therapy • Brands: Fetzima
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Fetzima
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Serotonin-norepinephrine reuptake inhibitor (SNRI) with relatively greater norepinephrine reuptake inhibition; extended-release formulation for major depressive disorder.
Metabolism & Half‑life
- Metabolism: CYP3A4, CYP2C8 (minor), CYP2C19 (minor), CYP2D6 (minor), CYP2J2 (minor)
- Half‑life: Single-dose mean 12 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- FETZIMA (levomilnacipran) extended-release capsules prescribing information — DailyMed (2025)
- Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 — Pharmacopsychiatry (2018)
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)
- CANMAT 2024 Clinical Guidelines for Major Depressive Disorder — Canadian Journal of Psychiatry (2024)